(function(){ var content_array=["
關于貝瑞基因<\/span><\/b> <\/p> \n 貝瑞基因(股票代碼:SZ000710)成立于2010年5月,是致力于應用高通量測序技術,為臨床醫學疾病篩查和診斷提供“無創式”整體解決方案的研發型生物科技公司。貝瑞基因已發展成為總部設在北京,覆蓋上海、青島、成都、重慶等多地醫學檢驗所與杭州生產基地的產業格局,并在香港地區成立香港雅士能基因科技有限公司(Xcelom),市場網絡覆蓋國內30多個省市自治區超過2000家醫院,共有1400多名員工,已成為基因檢測在臨床轉化領域的行業領導者,2017年8月成功登陸A股主板上市。<\/p> \n <\/p> \n 參考文獻<\/span><\/p> <\/td> \n <\/tr> \n [i] Elaine et al., Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72 400 specimens,European Journal of Human Genetics (2012) 20, 27-32<\/span><\/p> <\/td> \n <\/tr> \n [ii] Yi ningsu et al., Carrier screening for spinal muscular atrophy in 107,611 pregnant women during the period 2005-2009: a prospective population based cohort study,PLos ONE, Feb 2011, Vol 6 Issue 2.<\/span><\/p> <\/td> \n <\/tr> \n [iii]張曉青,王麗麗,余永國,傅啟華.脊髓性肌萎縮癥的三種基因診斷方法比較[J].中華檢驗醫學雜志,2015,38(1):16-20<\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n <\/p> \n 圖片 - https:\/\/photos.prnasia.com\/prnh\/20180418\/2108412-1-a<\/a> \n \n
\n \n \n \n
圖片 - https:\/\/photos.prnasia.com\/prnh\/20180418\/2108412-1-b<\/a>
圖片 - https:\/\/photos.prnasia.com\/prnh\/20180418\/2108412-1-c<\/a>
<\/p>"];
$("#dvExtra").html(content_array[0]);})();